Our end-to-end service offering spans Bioavailability/Bioequivalence (BA/BE) and Phase I studies, Phase II to Phase IV and PMS studies, medical writing, Biostatistics and Statistical Programming Services, Clinical Data Management (CDM), GCP Audits and training.

The portfolio has been developed specifically to help customers expedite the regulatory submission process and speed time to market.

The clinical affaris service portfolio is rounded off with ELC Group’s Good Clinical Practice (GCP) auditing, quality assessment and risk analysis services, plus GCP training and workshops for IEC/IRB.  All services are complemented by ELC Group’s expert medical writing capability for regulatory submissions, scientific communications and medico-marketing material.